<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407809</url>
  </required_header>
  <id_info>
    <org_study_id>1004011008</org_study_id>
    <nct_id>NCT01407809</nct_id>
  </id_info>
  <brief_title>Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy</brief_title>
  <acronym>VSSIIH</acronym>
  <official_title>Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Intracranial Hypertension (IIH) is a disease that affects mainly young people, and&#xD;
      is associated with headache and loss of vision. The medical and surgical management of IIH is&#xD;
      problematic and many patients are not treated effectively. Some cases of IIH are associated&#xD;
      with severe stenosis of the large veins of the brain and various researchers have recently&#xD;
      reported significant improvement in patients with IIH after the narrow veins of the brain&#xD;
      were treated with a stent. Our project aims to evaluate the safety and long-term efficacy of&#xD;
      venous sinus stenting in patients with severe IIH refractory to medical management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of procedure related and device related complications.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant cerebrospinal fluid (CSF) pressure reduction AND improvement of more than one grade in the Humphrey Field SITA Standard 24-2 Test grading scale.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Greater than 2 decibel (dB) mean deviation compared to the pre-operative field testing.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Idiopathic Intracranial Hypertension (IIH)</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venous Sinus Stenting</intervention_name>
    <description>Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Established diagnosis of Idiopathic Intracranial Hypertension according to the&#xD;
             criteria of the 2004 International Classification of Headache Disorders (Table 3).&#xD;
&#xD;
          3. Visual field loss: One of criteria A, B or C must be fulfilled.&#xD;
&#xD;
             A. Severe visual function loss, defined as grades 4 and 5 on the Humphrey Visual Field&#xD;
             Analyzer SITA Standard 24-2 Test grading scale (Table 4) at initial presentation.&#xD;
&#xD;
             B. Moderate visual function loss, defined as grade 3 on the Humphrey Visual Field&#xD;
             Analyzer SITA Standard 24-2 Test grading scale (Table 4) at presentation and failure&#xD;
             of treatment with acetazolamide (Diamox) given at efficient dose (2g/d or maximum&#xD;
             tolerated dose) or Topiramate (Topamax) given at efficient dose (maximum 150mg daily).&#xD;
             Failure is defined by the absence of visual function improvement after 1 month of&#xD;
             treatment and/or medication intolerance.&#xD;
&#xD;
             C. Mild visual function loss, defined as grades 0,1 or 2 on the Humphrey Visual Field&#xD;
             Analyzer SITA Standard 24-2 Test grading scale (Table 4) at presentation and a&#xD;
             worsening to moderate or greater visual function loss, defined as grades 3-5, after 1&#xD;
             month of treatment and/or medication intolerance.&#xD;
&#xD;
          4. Magnetic Resonance Venography (MRV) or Computed Tomography Venography (CTV)&#xD;
             demonstrating bilateral transverse sinus stenosis or unilateral transverse sinus&#xD;
             stenosis with contralateral transverse sinus hypoplasia or atresia. At least one of&#xD;
             the stenoses must cause â‰¥ 50% reduction of the sinus lumen diameter.&#xD;
&#xD;
          5. Signed informed consent obtained from the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athos Patsalides, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian/ Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypertension</mesh_term>
    <mesh_term>Pseudotumor Cerebri</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

